Sociedad Americana de Hirudoterapia

A novel protease-activated receptor 1 inhibitor from the leech Whitmania pigra

Pharmacology article published in Chinese Journal of Natural Medicines (2019)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Preclinical (animal)Farmacología salivalDesarrollo de fármacosGenómica y proteómicaRen SH, Liu ZJ, Cao Y et al. · Chinese journal of natural medicines, 2019

Abstract

Whitmania pigra has been used as a traditional Chinese medicine (TCM) for promoting blood circulation, alleviating blood coagulation, activating meridians and relieving stasis for several hundred years. However, the therapeutic components of this species, especially proteins and peptides were poorly exploited. Until now only a few of them were obtained by using chromatographic isolation and purification. In recent decade, transcriptome techniques were rapidly developed, and have been used to fully reveal the functional components of many animal venoms. In the present study, the cDNA of the salivary gland of Whitmania pigra was sequenced by illumina and the transcriptome was assembled by using Trinity. The proteome were analysed by LC-MS/MS. Based on the data of the transcriptome and the proteome, a potential antiplatelet protein named pigrin was found. Pigrin was cloned and expressed using P. pastoris GS115. The antiplatelet andantithrombotic bioactivities of pigrin were tested by using aggregometer and the rat arterio-venous shunt thrombosis model, respectively. Thebleeding time of pigrin was measured by a mice tail cutting method. The docking of pigrin and protease-activated receptor 1 (PAR1) or collagen were conducted using the ZDOCK Server. Pigrin was able to selectively inhibit platelet aggregation stimulated by PAR1 agonist and collagen. Pigrin attenuated thrombotic formation in vivo in rat, while did not prolong bleeding time at its effective dosage. There are significant differences in the key residues participating in binding of Pigrin-Collagen complex from Pigrin-PAR1 complex. In conclusion,a novel PAR1 inhibitor pigrin was found from the leech Whitmania pigra. This study helped to elucidate the mechanism of the leech for the treatment of cardiovascular disorder.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsDisease Models, AnimalFibrinolytic AgentsGene Expression ProfilingLeechesMice, Inbred ICRModels, MolecularPlatelet AggregationPlatelet Aggregation InhibitorsProteomicsRats, Sprague-Dawley

Resumen

Combined transcriptome and proteome of Whitmania pigra salivary glands identifies pigrin, a novel PAR1 inhibitor that selectively inhibits PAR1-agonist and collagen-stimulated platelet aggregation in vivo without prolonging bleeding time.

Por qué esto importa para la hirudoterapia

Este estudio identificó pigrin, un nuevo inhibidor del receptor 1 activado por proteasa (PAR1) de la sanguijuela Whitmania pigra, mediante análisis combinado de transcriptoma y proteoma seguido de expresión recombinante en Pichia pastoris. Las pruebas funcionales mostraron que pigrin inhibió selectivamente la agregación plaquetaria estimulada por agonista de PAR1 y colágeno, atenuó la formación de trombos en un modelo de derivación arteriovenosa en rata y no prolongó el tiempo de sangrado en ratones a su dosificación antitrombótica efectiva. Para el dominio de ASH, pigrin representa un compuesto bioactivo recién descubierto derivado de sanguijuela con propiedades antitrombóticas, ampliando el repertorio farmacológico conocido del secretoma de la sanguijuela. Advertencia: se trata de un estudio preclínico que utiliza ensayos in vitro y modelos animales en roedores; los hallazgos no se han validado en ensayos clínicos en humanos, y el resumen no aborda la práctica de la hirudoterapia con sanguijuelas vivas.

Citación

A novel protease-activated receptor 1 inhibitor from the leech Whitmania pigra.

Ren SH, Liu ZJ, Cao Y et al. · Chinese journal of natural medicines, 2019

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.